FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

Friday

 

MS: Patients Make Gains on High-Dose Biotin


Vitamin B7 Biotin

High-dose biotin may be an effective treatment for progressive multiple sclerosis (MS), according to recent research. A paper published in Multiple Sclerosis Journal, authored by Professor Ayman Tourbah of the Department of Neurology and Faculty of Medicine at the University Hospital Center in Reims, France, and colleagues describes the study.

The researchers explain, “MD1003 is an oral formulation of high-dose pharmaceutical-grade biotin (10,000 times the recommended daily intake) that recently demonstrated promising efficacy in patients with not-active progressive MS.” They conducted the present study to “assess whether MD1003 could reverse disability progression,” they say.  

In order to investigate, the researchers conducted a “12-month, randomized, double-blind, placebo-controlled trial followed by an open-label 12-month extension phase where all patients received MD1003.” Participants were drawn from 16 centers across France. The primary outcome measure was an improvement in Expanded Disability Status Scale (EDSS).  

“Between October 2013 and January 2014, 166 patients were screened and 154 were randomized to MD1003 or placebo,” say the authors. Of those, 103 received MD1003 and 51 received placebo. The authors further report that 12 patients in the MD1003 withdrew, six of those due to adverse events (AEs); nine in the placebo group withdrew, seven of those due to AEs.  

The researchers say, “A total of 13 patients treated with MD1003 had a reduction in MS-related disability at month nine, confirmed at month 12, compared with none in the placebo arm.” The results were similar after the extension period: “A total of 12 of the 91 patients initially treated with MD1003 had reduced MS-related disability at 18 months, including 10 of the 13 patients who responded during the placebo-controlled phase.”  

Although there were improvements in EDSS, the authors note, “More new or enlarging MRI lesions occurred in the MD1003 arm than in the placebo arm during the double-blind phase.” They also report observing that MD1003 appears to interfere with biotin-based tests in the laboratory, which could be a safety concern.  


Story Source: The above story is based on materials provided by HCPLIVE
Note: Materials may be edited for content and length


Go to Newer News Go to Older News